-+ 0.00%
-+ 0.00%
-+ 0.00%

VOR BIOPHARMA - TELITACICEPT SUSTAINS PROTEINURIA REDUCTION THROUGH 104 WEEKS WITH FAVORABLE SAFETY PROFILE

Reuters·10/22/2026 20:05:00

Please log in to view news